BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 11326646)

  • 1. Improved sensitivity of fuzzy logic based tumor marker profiles for diagnosis of pancreatic carcinoma versus benign pancreatic disease.
    Halm U; Rohde N; Klapdor R; Reith HB; Thiede A; Etzrodt G; Mössner J; Keller T
    Anticancer Res; 2000; 20(6D):4957-60. PubMed ID: 11326646
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fuzzy logic-based tumor marker profiles including a new marker tumor M2-PK improved sensitivity to the detection of progression in lung cancer patients.
    Schneider J; Peltri G; Bitterlich N; Neu K; Velcovsky HG; Morr H; Katz N; Eigenbrodt E
    Anticancer Res; 2003; 23(2A):899-906. PubMed ID: 12820320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fuzzy logic-based tumor marker profiles improved sensitivity of the detection of progression in small-cell lung cancer patients.
    Schneider J; Peltri G; Bitterlich N; Philipp M; Velcovsky HG; Morr H; Katz N; Eigenbrodt E
    Clin Exp Med; 2003 Feb; 2(4):185-91. PubMed ID: 12624710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved sensitivity in the diagnosis of gastro-intestinal tumors by fuzzy logic-based tumor marker profiles including the tumor M2-PK.
    Schneider J; Bitterlich N; Schulze G
    Anticancer Res; 2005; 25(3A):1507-15. PubMed ID: 16033052
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fuzzy logic-based tumor-marker profiles improved sensitivity in the diagnosis of lung cancer.
    Schneider J; Bitterlich N; Velcovsky HG; Morr H; Katz N; Eigenbrodt E
    Int J Clin Oncol; 2002 Jun; 7(3):145-51. PubMed ID: 12109515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Does cholestasis change the clinical usefulness of CA 19-9 in pacreatobiliary cancer?].
    Mery CM; Duarte-Rojo A; Paz-Pineda F; Gómez E; Robles-Díaz G
    Rev Invest Clin; 2001; 53(6):511-7. PubMed ID: 11921523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Accuracy of imaging techniques and tumor markers in the diagnosis of pancreatic cancer].
    Clavé P; Boadas J; González-Carro P; Mora J; Pérez C; Martínez A; Roca M; Lluís F; Farré A
    Gastroenterol Hepatol; 1999; 22(7):335-41. PubMed ID: 10535205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of different tumor markers in the early diagnosis and prognosis of pancreatic carcinoma and chronic pancreatitis.
    Hámori J; Arkosy P; Lenkey A; Sápy P
    Acta Chir Hung; 1997; 36(1-4):125-7. PubMed ID: 9408313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.
    Ni XG; Bai XF; Mao YL; Shao YF; Wu JX; Shan Y; Wang CF; Wang J; Tian YT; Liu Q; Xu DK; Zhao P
    Eur J Surg Oncol; 2005 Mar; 31(2):164-9. PubMed ID: 15698733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gallbladder bile tumor marker quantification for detection of pancreato-biliary malignancies.
    Brockmann J; Emparan C; Hernandez CA; Sulkowski U; Dietl KH; Menzel J; Wolters H; Glodny B; Senninger N
    Anticancer Res; 2000; 20(6D):4941-7. PubMed ID: 11326643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of tumor marker CA 242 with CA 19-9 and carcinoembryonic antigen (CEA) in pancreatic cancer.
    Ozkan H; Kaya M; Cengiz A
    Hepatogastroenterology; 2003; 50(53):1669-74. PubMed ID: 14571813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the diagnostic value of serum tumor markers, and fecal k-ras and p53 gene mutations for pancreatic cancer.
    Wu X; Lu XH; Xu T; Qian JM; Zhao P; Guo XZ; Yang XO; Jiang WJ
    Chin J Dig Dis; 2006; 7(3):170-4. PubMed ID: 16808798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preoperative differential diagnosis of benign and malignant pancreatic lesions--the value of pancreatic secretory trypsin inhibitor, procarboxypeptidase B, CA19-9 and CEA.
    Cerwenka H; Aigner R; Quehenberger F; Werkgartner G; Bacher H; Hauser H; Mischinger HJ
    Hepatogastroenterology; 1997; 44(16):1117-21. PubMed ID: 9261609
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical value of serum TAG-72 as a tumor marker for pancreatic carcinoma. Comparison with CA 19-9.
    Pasquali C; Sperti C; D'Andrea AA; Costantino V; Filipponi C; Pedrazzoli S
    Int J Pancreatol; 1994 Jun; 15(3):171-7. PubMed ID: 7930777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decision guarantee in tumour marker analysis: a cut-off independent assessment.
    Bitterlich N; Schneider J
    Anticancer Res; 2007; 27(4A):1933-9. PubMed ID: 17649799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The diagnostic importance of CEA and CA 19-9 for the early diagnosis of pancreatic carcinoma.
    Nazli O; Bozdag AD; Tansug T; Kir R; Kaymak E
    Hepatogastroenterology; 2000; 47(36):1750-2. PubMed ID: 11149048
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnosis of pancreatic cancer by cytology and measurement of oncogene and tumor markers in pure pancreatic juice aspirated by endoscopy.
    Nakaizumi A; Uehara H; Takenaka A; Uedo N; Sakai N; Yano H; Ohigashi H; Ishikawa O; Ishiguro S; Sugano K; Tatsuta M
    Hepatogastroenterology; 1999; 46(25):31-7. PubMed ID: 10228761
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A fuzzy-classifier using a marker panel for the detection of lung cancers in asbestosis patients.
    Schneider J; Bitterlich N; Kotschy-Lang N; Raab W; Woitowitz HJ
    Anticancer Res; 2007; 27(4A):1869-77. PubMed ID: 17649786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TUM2-PK (pyruvate kinase type tumor M2), CA19-9 and CEA in patients with benign, malignant and metastasizing pancreatic lesions.
    Cerwenka H; Aigner R; Bacher H; Werkgartner G; el-Shabrawi A; Quehenberger F; Mischinger HJ
    Anticancer Res; 1999; 19(1B):849-51. PubMed ID: 10216504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of serum tumor markers in the diagnosis and treatment of patients with pancreatic cancer.
    Jiang XT; Tao HQ; Zou SC
    Hepatobiliary Pancreat Dis Int; 2004 Aug; 3(3):464-8. PubMed ID: 15313690
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.